Stem cell technology for the study and treatment of motor neuron diseases

Regenerative Medicine

Volumn 6, Issue 2, 2011, Pages 201-213

  Lunn, J Simon ^a   Sakowski, Stacey A ^a   Federici, Thais ^b   Glass, Jonathan D ^b   Boulis, Nicholas M ^b   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyotrophic lateral sclerosis; induced pluripotent stem cells; motor neuron disease; Phase I clinical trial; spinal muscular atrophy; stem cells; translational medicine

Indexed keywords

BETA LACTAM ANTIBIOTIC; BRAIN DERIVED NEUROTROPHIC FACTOR; CEFTRIAXONE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; SUPEROXIDE DISMUTASE; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; DISEASE SEVERITY; EPIGENETICS; FEASIBILITY STUDY; GENE MUTATION; GRAFT SURVIVAL; HOMOZYGOSITY; HUMAN; LETHALITY; MOTOR NEURON DISEASE; MUSCLE STRENGTH; MUSCLE TONE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SAFETY; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MODELS, BIOLOGICAL; MOTOR NEURON DISEASE; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSLATIONAL RESEARCH;

EID: 79952671539     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.11.6     Document Type: Review

References (120)

1. Vazin T, Freed WJ: Human embryonic stem cells: derivation, culture, and differentiation: a review. Restor. Neurol. Neurosci. 28(4), 589-603 (2010).
2. Murry CE, Keller G: Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132(4), 661-680 (2008). (Pubitemid 351260059)
3. Kim SU: Human neural stem cells genetically modifed for brain repair in neurological disorders. Neuropathology 24(3), 159-171 (2004). (Pubitemid 39279676)
4. Xu L, Yan J, Chen D et al.: Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 82(7), 865-875 (2006). (Pubitemid 44564030)
5. Garzon-Muvdi T, Quinones-Hinojosa A: Neural stem cell niches and homing: recruitment and integration into functional tissues. ILAR J. 51(1), 3-23 (2009).
6. Caplan AI: Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell Physiol. 213(2), 341-347 (2007). (Pubitemid 47509711)
7. Mezey E, Mayer B, Nemeth K: Unexpected roles for bone marrow stromal cells (or MSCs): a real promise for cellular, but not replacement, therapy. Oral Dis. 16(2), 129-135 (2010).
8. Robinson AP, Foraker JE, Ylostalo J, Prockop DJ: Human stem/progenitor cells from bone marrow enhance glial differentiation of rat neural stem cells: a role for transforming growth factor-β and Notch signaling. Stem Cells Dev. 20(2), 289-300 (2010).
9. Li JM, Zhu H, Lu S et al.: Migration and differentiation of human mesenchymal stem cells in the normal rat brain. Neurol. Res. 33(1), 84-92 (2010).
10. Lunn JS, Hefferan MP, Marsala M, Feldman EL: Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery Growth Factors 27(3), 133-140 (2009).
11. Hu BY, Zhang SC: Directed differentiation of neural-stem cells and subtype-specifc neurons from hESCs. Methods Mol. Biol. 636, 123-137 (2010).
12. Guo X, Johe K, Molnar P, Davis H, Hickman J: Characterization of a human fetal spinal cord stem cell line, NSI-566RSC, and its induction to functional motoneurons. J. Tissue Eng. Regen. Med. 4(3), 181-193 (2010).
13. Hu BY, Zhang SC: Differentiation of spinal motor neurons from pluripotent human stem cells. Nat. Protoc. 4(9), 1295-1304 (2009).
14. Thonhoff JR, Ojeda L, Wu P: Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis. Curr. Stem Cell Res. Ther. 4(3), 178-199 (2009).
15. Jordan PM, Ojeda LD, Thonhoff JR et al.: Generation of spinal motor neurons from human fetal brain-derived neural stem cells: role of basic fbroblast growth factor. J. Neurosci. Res. 87(2), 318-332 (2009).
16. Lepore AC, Rauck B, Dejea C et al.: Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 11(11), 1294-1301 (2008).
17. Suzuki M, Svendsen CN: Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci. 31(4), 192-198 (2008).
18. Feldman EL, Goldman L, Ausiello D: Amyotrophic lateral sclerosis and other motor neuron diseases. In: Cecil Textbook of Medicine. Saunders, PA, USA, 2316-2319 (2004).
19. Rosen DR, Siddique T, Patterson D et al.: Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62 (1993). (Pubitemid 23087289)
20. Gonzalez DE, Aguilar JL, Echaniz-Laguna A et al.: Amyotrophic lateral sclerosis: all roads lead to Rome. J. Neurochem. 101(5), 1153-1160 (2007). (Pubitemid 46718806)
21. Turner BJ, Talbot K: Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85(1), 94-134 (2008).
22. Ilieva H, Polymenidou M, Cleveland DW: Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187(6), 761-772 (2009).
23. Kabashi E, Valdmanis PN, Dion P et al.: TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 40(5), 572-574 (2008). (Pubitemid 351601218)
24. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL et al.: Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323(5918), 1205-1208 (2009).
25. Lagier-Tourenne C, Cleveland DW: Rethinking ALS: the FUS about TDP-43. Cell 136(6), 1001-1004 (2009).
26. Sreedharan J, Blair IP, Tripathi VB et al.: TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319(5870), 1668-1672 (2008). (Pubitemid 351432505)
27. Howland DS, Liu J, She Y et al.: Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl Acad. Sci. USA 99, 1604-1609 (2002). (Pubitemid 34136539)
28. Gurney Me, Pu H, Chiu Ay et al.: Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264(5166), 1772-1775 (1994). (Pubitemid 24227760)
29. Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL: Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 40(2), 404-414 (2010).
30. Festoff BW, Suo Z, Citron BA: Prospects for the pharmacotherapy of amyotrophic lateral sclerosis: old strategies and new paradigms for the third millennium. CNS Drugs 17, 699-717 (2003). (Pubitemid 37000008)
31. Raoul C, Bbas-Terki T, Bensadoun JC et al.: Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11, 423-428 (2005). (Pubitemid 40562333)
32. Rothstein JD, Patel S, Regan MR et al.: β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-77 (2005). (Pubitemid 40101145)
33. Ji HF, Shen L, Zhang HY: β-lactam antibiotics are multipotent agents to combat neurological diseases. Biochem. Biophys. Res. Commun. 333, 661-663 (2005). (Pubitemid 40854211)
34. Schutz B, Reimann J, Dumitrescu-Ozimek L et al.: The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25, 7805-7812 (2005). (Pubitemid 41208652)
35. Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF: Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. 58, 258-265 (2005). (Pubitemid 41098883)
36. Park JH, Hong YH, Kim HJ et al.: Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neurosci. Lett. 413(3), 265-269 (2007).
37. Bilic E, Rudan I, Kusec V, Zurak N, Delimar D, Zagar M: Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fuid and serum between patients with motor neuron disease and healthy controls. Eur. J. Neurol. 13(12), 1340-1345 (2006). (Pubitemid 44736644)
38. Moreau C, Devos D, Brunaud-Danel V et al.: Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J. Neurol. Neurosurg. Psychiatry 77(2), 255-257 (2006). (Pubitemid 43220855)
39. Dodge JC, Treleaven CM, Fidler JA et al.: AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 18(12), 2075-2084 (2010).
40. Dodge JC, Haidet AM, Yang W et al.: Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modifcation of aberrant glial cell activity. Mol. Ther. 16(6), 1056-1064 (2008). (Pubitemid 351737070)
41. Lunn JS, Sakowski SA, Kim B, Rosenberg AA, Feldman EL: Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. Dev. Neurobiol. 69(13), 871-884 (2009).
42. Sakowski SA, Heavener SB, Lunn JS et al.: Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression. Gene Ther. 16(11), 1292-1299 (2009).
43. Sakowski SA, Schuyler AD, Feldman EL: Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 10(2), 63-73 (2009).
44. Borasio GD, Robberecht W, Leigh PN et al.: A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51(2), 583-586 (1998). (Pubitemid 28406343)
45. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52(7), 1427-1433 (1999).
46. Miller RG, Petajan JH, Bryan WW et al.: A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. 39(2), 256-260 (1996). (Pubitemid 26071576)
47. Lai EC, Felice KJ, Festoff BW et al.: Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49(6), 1621-1630 (1997). (Pubitemid 28015128)
48. Sorenson EJ, Windbank AJ, Mandrekar JN et al.: Subcutaneous IGF-1 is not benefcial in 2-year ALS trial. Neurology 71(22), 1770-1775 (2008).
49. Wee CD, Kong L, Sumner CJ: The genetics of spinal muscular atrophies. Curr. Opin. Neurol. 23(5), 450-458 (2010).
50. Rochette CF, Gilbert N, Simard LR: SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum. Genet. 108(3), 255-266 (2001). (Pubitemid 32293674)
51. Lorson CL, Rindt H, Shababi M: Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum. Mol. Genet. 19(R1), R111-R118 (2010).
52. Coady TH, Shababi M, Tullis GE, Lorson CL: Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol. Ther. 15(8), 1471-1478 (2007). (Pubitemid 47099304)
53. Schrank B, Gotz R, Gunnersen JM et al.: Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl Acad. Sci. USA 94(18), 9920-9925 (1997). (Pubitemid 27408166)
54. Jablonka S, Schrank B, Kralewski M, Rossoll W, Sendtner M: Reduced survival motor neuron (smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. Hum. Mol. Genet. 9(3), 341-346 (2000). (Pubitemid 30098726)
55. Park GH, Kariya S, Monani UR: Spinal muscular atrophy: new and emerging insights from model mice. Curr. Neurol. Neurosci. Rep. 10(2), 108-117 (2010).
56. Hsieh-Li HM, Chang JG, Jong YJ et al.: A mouse model for spinal muscular atrophy. Nat. Genet. 24(1), 66-70 (2000). (Pubitemid 30041423)
57. -/- mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9(3), 333-339 (2000). (Pubitemid 30098725)
58. Gunaseeli I, Doss MX, Antzelevitch C, Hescheler J, Sachinidis A: Induced pluripotent stem cells as a model for accelerated patient-and disease-specifc drug discovery. Curr. Med. Chem. 17(8), 759-766 (2010).
59. Inoue H: Neurodegenerative disease-specifc induced pluripotent stem cell research. Exp. Cell Res. 316(16), 2560-2564 (2010).
60. Kiskinis E, Eggan K: Progress toward the clinical application of patient-specifc pluripotent stem cells. J. Clin. Invest. 120(1), 51-59 (2010).
61. Marchetto MC, Winner B, Gage FH: Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum. Mol. Genet. 19(R1), R71-R76 (2010).
62. Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fbroblasts by defned factors. Cell 131(5), 861-872 (2007). (Pubitemid 350138099)
63. Yamanaka S, Blau HM: Nuclear reprogramming to a pluripotent state by three approaches. Nature 465(7299), 704-712 (2010).
64. Yamanaka S: Strategies and new developments in the generation of patient-specifc pluripotent stem cells. Cell Stem Cell 1(1), 39-49 (2007). (Pubitemid 46865811)
65. Yamanaka S: Induction of pluripotent stem cells from mouse fbroblasts by four transcription factors. Cell Prolif. 41(Suppl. 1), 51-56 (2008). (Pubitemid 350295862)
66. Zhou H, Ding S: Evolution of induced pluripotent stem cell technology Curr. Opin. Hematol. 17(4), 276-280 (2010).
67. Maherali N, Hochedlinger K: Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3(6), 595-605 (2008).
68. Yu J, Hu K, Smuga-Otto K et al.: Human induced pluripotent stem cells free of vector and transgene sequences. Science 324(5928), 797-801 (2009).
69. Yu J, Thomson JA: Pluripotent stem cell lines. Genes Dev. 22(15), 1987-1997 (2008).
70. Kim D, Kim CH, Moon JI et al.: Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4(6), 472-476 (2009).
71. Zhang N, An MC, Montoro D, Ellerby LM: Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr. 2, RRN1193 (2010).
72. Soldner F, Hockemeyer D, Beard C et al.: Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136(5), 964-977 (2009).
73. Liu J, Verma PJ, Evans-Galea MV et al.: Generation of induced pluripotent stem cell lines from Friedreich ataxia patients. Stem Cell Rev. (2010) (Epub ahead of print).
74. Dimos JT, Rodolfa KT, Niakan KK et al.: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321(5893), 1218-1221 (2008).
75. Ebert AD, Yu J, Rose FF Jr et al.: Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457(7227), 277-280 (2009).
76. Mikkelsen TS, Hanna J, Zhang X et al.: Dissecting direct reprogramming through integrative genomic analysis. Nature 454(7200), 49-55 (2008) (Pubitemid 351931978)
77. H u BY, We ick J P, Yu J et al.: Ne u ral differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency Proc. Natl Acad. Sci. USA 107(9), 4335-4340 (2010).
78. Kane NM, Nowrouzi A, Mukherjee S et al.: Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Mol. Ther. 18(12), 2139-2145 (2010).
79. Meissner A: Epigenetic modifcations in pluripotent and differentiated cells. Nat. Biotechnol. 28(10), 1079-1088 (2010).
80. Rolletschek A, Wobus AM: Induced human pluripotent stem cells: promises and open questions. Biol. Chem. 390(9), 845-849 (2009).
81. Stadtfeld M, Apostolou E, Akutsu H et al.: Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465(7295), 175-181 (2010).
82. Polo JM, Liu S, Figueroa ME et al.: Cell type of origin infuences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28(8), 848-855 (2010).
83. Corti S, Locatelli F, Donadoni C et al.: Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 127(Pt 11), 2518-2532 (2004). (Pubitemid 39472980)
84. + cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Hum. Mol. Genet. 19(19), 3782-3796 (2010).
85. Mitrecic D, Nicaise C, Gajovic S, Pochet R: Distribution, differentiation, and survival of intravenously administered neural stem cells in a rat model of amyotrophic lateral sclerosis. Cell Transplant. 19(5), 537-548 (2010).
86. Ohnishi S, Ito H, Suzuki Y et al.: Intra-bone marrow-bone marrow transplantation slows disease progression and prolongs survival in G93A mutant SOD1 transgenic mice, an animal model mouse for amyotrophic lateral sclerosis. Brain Res. 1296, 216-224 (2009).
87. Garbuzova-Davis S, Willing AE, Zigova T et al.: Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J. Hematother. Stem Cell Res. 12(3), 255-270 (2003). (Pubitemid 36736737)
88. Garbuzova-Davis S, Sanberg CD, Kuzmin-Nichols N et al.: Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS ONE 3(6), e2494 (2008).
89. Chi L, Ke Y, Luo C et al.: Motor neuron degeneration promotes neural progenitor cell proliferation, migration, and neurogenesis in the spinal cords of amyotrophic lateral sclerosis mice. Stem Cells 24(1), 34-43 (2006).
90. Suzuki M, Mchugh J, Tork C et al.: GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 2(1), e689 (2007).
91. Xu L, Ryugo DK, Pongstaporn T, Johe K, Koliatsos VE: Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J. Comp. Neurol. 514(4), 297-309 (2009).
92. Park S, Kim HT, Yun S et al.: Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp. Mol. Med. 41(7), 487-500 (2009).
93. Suzuki M, Mchugh J, Tork C et al.: Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther. 16(12), 2002-2010 (2008).
94. Corti S, Nizzardo M, Nardini M et al.: Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J. Clin. Invest. 118(10), 3316-3330 (2008).
95. Corti S, Nizzardo M, Nardini M et al.: Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 133 (Pt 2), 465-481 (2010).
96. Hung CW, Liou YJ, Lu SW et al.: Stem cell-based neuroprotective and neurorestorative strategies. Int. J. Mol. Sci. 11(5), 2039-2055 (2010).
97. Li JY, Christophersen NS, Hall V, Soulet D, Brundin P: Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci. 31(3), 146-153 (2008).
98. Raore B, Federici T, Taub J et al.: Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. Spine 36(3), E164-E171 (2011).
99. Cizkova D, Kakinohana O, Kucharova K et al.: Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells. Neuroscience 147(2), 546-560 (2007). (Pubitemid 46915483)
100. Yan J, Xu L, Welsh AM et al.: Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med. 4(2), e39 (2007).
101. Usvald D, Vodicka P, Hlucilova J et al.: Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplant. 19(9), 1103-1122 (2010).
102. Riley JP, Raore B, Taub JS, Federici T, Boulis NM: Platform and cannula design improvements for spinal cord therapeutics delivery. Neurosurgery (2011) (In Press).
103. Chen L, Huang H, Zhang J et al.: Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 21(9), 961-966 (2007).
104. Deda H, Inci MC, Kurekci AE et al.: Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 11(1), 18-25 (2009).
105. Federici T, Riley J, Park J, Bain M, Boulis NM: Preclinical safety validation of a stabilized viral vector direct injection approach to the cervical spinal cord. Clin. Transl. Sci. 2(2), 165-167 (2009).
106. Mazzini L, Ferrero I, Luparello V et al.: Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp. Neurol. 223(1), 229-237 (2010).
107. Riley J, Butler J, Park J et al.: Targeted spinal cord therapeutics delivery: stabilized platform and MER guidance validation. Stereotact. Funct. Neurosurg 86(2), 67-74 (2007). (Pubitemid 351341531)
108. Karussis D, Karageorgiou C, Vaknin-Dembinsky A et al.: Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 67(10), 1187-1194 (2010).
109. Dantuma E, Merchant S, Sugaya K: Stem cells for the treatment of neurodegenerative diseases. Stem Cell Res. Ther. 1(5), 37 (2010).
110. Gogel S, Gubernator M, Minger SL: Progress and prospects: stem cells and neurological diseases. Gene Therapy 18(1), 1-6 (2011).
111. Miller RH: The promise of stem cells for neural repair. Brain Res. 1091(1), 258-264 (2006). (Pubitemid 43993886)
112. Webber DJ, Minger SL: Therapeutic potential of stem cells in central nervous system regeneration. Curr. Opin. Investig Drugs 5(7), 714-719 (2004).
113. Yu D, Silva GA: Stem cell sources and therapeutic approaches for central nervous system and neural retinal disorders. Neurosurg. Focus 24(3-4), E1 1 (2008).
114. Geron Corporation: World's frst clinical trial of human embryonic stem cell therapy cleared. Regen. Med. 4(2), 161 (2009).
115. Lopez-Gonzalez R, Kunckles P, Velasco I: Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells. Cell Transplant. 18(10), 1171-1181 (2009).
116. + modify disease progression in an amyotrophic lateral sclerosis model. Brain 130(Pt 5), 1289-1305 (2007). (Pubitemid 47355948)
117. Rizvanov AA, Guseva DS, Salafutdinov II et al.: Genetically modifed human umbilical cord blood cells expressing vascular endothelial growth factor and fbroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Exp. Biol. Med. (Maywood) 236(1), 91-98 (2011).
118. Kim H, Kim HY, Choi MR et al.: Dose-dependent effcacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci. Lett. 468(3), 190-194 (2010).
119. Hwang DH, Lee HJ, Park IH et al.: Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 16(10), 1234-1244 (2009).
120. Klein SM, Behrstock S, Mchugh J et al.: GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther. 16(4), 509-521 (2005). (Pubitemid 40647148)